Scholarlink

<p>Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20–30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&amp;E)-stained pathological slides are used for routine diagnosis of cancer type, they may also contain diagnostically useful information about treatment response. Our study demonstrates that combining H&amp;E-stained whole slide images (WSIs) with proteomic signatures using a multimodal deep learning framework significantly improves the prediction of platinum response in both discovery and validation cohorts. This method outperforms the Homologous Recombination Deficiency (HRD) score in predicting platinum response and overall patient survival. Our study suggests that histology and proteomics contain complementary information about biological processes determining response to first line platinum treatment in HGSOC. This integrative approach has the potential to improve personalized treatment and provide insights into the therapeutic vulnerabilities of HGSOC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月26日

查看全文
  • Oz Kilim,
  • Alex Olar,
  • András Biricz,
  • Lilla Madaras,
  • Péter Pollner,
  • Zoltán Szállási,
  • Zsofia Sztupinszki,
  • István Csabai

摘要

Patients with High-Grade Serous Ovarian Cancer (HGSOC) exhibit varied responses to treatment, with 20–30% showing de novo resistance to platinum-based chemotherapy. While hematoxylin-eosin (H&E)-stained pathological slides are used for routine diagnosis of cancer type, they may also contain diagnostically useful information about treatment response. Our study demonstrates that combining H&E-stained whole slide images (WSIs) with proteomic signatures using a multimodal deep learning framework significantly improves the prediction of platinum response in both discovery and validation cohorts. This method outperforms the Homologous Recombination Deficiency (HRD) score in predicting platinum response and overall patient survival. Our study suggests that histology and proteomics contain complementary information about biological processes determining response to first line platinum treatment in HGSOC. This integrative approach has the potential to improve personalized treatment and provide insights into the therapeutic vulnerabilities of HGSOC.